in its decision of june the latter confirmed the patent office s rejection of a patent for glivec denying significantly enhanced efficacy of glivec under article d over a previously known molecule see the ipab decision in novartis ag v union of india et al business standard of july in addition the ipab ruled that because of the price charged for glivec poor cancer patients in india would not be able to afford the drug which in turn would threaten many people s lives and thus create public disorder in the country p of the decision